Cognition Conversations

Featuring:

Brendan Kelley, MD (moderator), UT Southwestern Medical Center, Professor and Clinical Vice Chair in the Department of Neurology

Samantha K. Holden, MD, MS, FAAN, University of Colorado School of Medicine, Associate Professor of Neurology, Vice Chair for Outpatient Neurology Services

Carla Preyer, Salon Owner, Inspirational Speaker, Care Partner to her Husband, Patrick

Linda Szypula Ed.D., Science Teacher, Care Partner to her Husband, James

Index:

0:00 Introduction

2:00 Caregiver Distress and Symptom Burden

16:14 Measuring Meaningful Changes in a Clinical Trial

22:09 Closing remarks

Featuring:

Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer

James E. Galvin, MD, MPH, University of Miami, Director of the Comprehensive Center for Brain Health, Miller School of Medicine

Lawrence S. Honig, MD, PhD, FAAN, Columbia University, Professor of Neurology, Irving Medical Center

David Shprecher, D.O., Banner Sun Health Research Institute, Movement Disorder Director, Banner Sun Health
Clinical Associate Professor, University of Arizona

Index:

0:00 Introduction

0:45 Comparing Alzheimer’s disease and DLB

5:02 SHIMMER Design and Outcomes

10:22 Metrics for Success in a Signal-finding Study

Featuring:

Anthony Caggiano, M.D., Ph.D. (moderator)

Cognition Therapeutics, Chief Medical Officer

Mary Hamby, Ph.D. (moderator)

Cognition Therapeutics, Vice President of Research

Everard (Jort) Vijverberg, MD, PhD

Alzheimer Center at Amsterdam University Medical Center, Neurologist and CNS Trial Specialist

Tara Spires Jones, DPhil

University of Edinburgh, Personal Chair of Neurodegeneration and Deputy Director of the Centre for Discovery Brain Sciences

Index:

0:00 Introduction

3:49 Findings from SEQUEL

6:45 Clinical observations of CT1812 engagement

9:08 Proteomic evidence of CT1812 engagement

11:52 CT1812’s ongoing Phase 2 study

Featuring:

Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer

Willem de Haan, M.D., Ph.D., Alzheimer Center at Amsterdam University Medical Center, Neurologist and Senior Researcher

Philip Scheltens, M.D., EQT Life Sciences, Partner and Head of Dementia Fund, Former Director of the Alzheimer Center at Amsterdam University Medical Center

Index:

0:00 Introduction

0:44 Rationale for the SEQUEL Study Design

2:10 EEG in neurodegenerative diseases

4:33 Findings from SEQUEL

9:52 Key Takeaways

Featuring:

Anthony Caggiano, M.D., Ph.D., Chief Medical Officer, Cognition Therapeutics

C. Gustavo De Moraes, M.D., Ph.D. (moderator), Chief Medical Officer, Ora (CRO), and Associate Professor of Clinical Ophthalmology, Columbia University

Jeffrey S. Heier, M.D., Director of the Vitreoretinal Service & Retina Research, Ophthalmic Consultants of Boston

Peter K. Kaiser, M.D., Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine

Featuring:

Mary Hamby, Ph.D., Vice President of Research, Cognition Therapeutics

Charlotte Teunissen, Ph.D. (moderator), Amsterdam University Medical Center, Professor of Clinical Neurochemistry

Nicholas Seyfried, Ph.D., Emory University School of Medicine, Professor of Biochemistry and Neurology , Director of the Emory Integrated Proteomics Core

Henrik Zetterberg, MD, Ph.D., Gothenburg University, Professor of Neuroscience

Group Leader of the UK Dementia Research Institute

Index:

0:00 Introduction

01:53 Utility of Proteomic Analysis in Alzheimer’

03:20 Review of Proteomics Findings from AD/PD 202

08:36 Key Learnings

Featuring:

Anthony Caggiano, M.D., Ph.D., Chief Medical Officer and Head of Research & Development, Cognition Therapeutics

Brendan Kelley, M.D. (moderator), University of Texas SW, Vice Chair for Clinical Operations at the Peter O’Donnell Jr. Brain Institute and a Professor in the Department of Neurology

Sarah B. Berman, M.D., Ph.D., University of Pittsburgh, Associate Professor in the Departments of Neurology and Clinical & Translational Science and Director of DLB Programs at the ARDC

James Leverenz, M.D., Cleveland Clinic, Director of the Lou Ruvo Center for Brain Health

David Shprecher, D.O., Banner Sun Health Research Institute, Movement Disorder Director

University of Arizona, Clinical Associate Professor

Index:

0:00 Introduction

01:09 Part I: The Intersection of Alzheimer’s and DLB

07:23 Biomarker Tests for DLB

09:11 Part II: Practical insights for community HCPs

09:40 Frequency of missed or delayed diagnosis of DLB

12:48 Facets of patient-reported memory loss

19:46 Nuances of psychological symptoms

24:23 Cognitive Fluctuations

Featuring:

Lisa Ricciardi, President & Chief Executive Officer, Cognition Therapeutics

Norma Loeb, Lewy Body Dementia Resource Center, Founder and Executive Director

Mary Lou Falcone, M.L. FALCONE, Public Relations

Board member, LBD Resource Center

Author of “I Didn’t See It Coming, a Memoir of Love, Loss, and Lewy Body Dementia”

Index:

0:00 Introduction

2:30 Key symptoms and signs of Lewy body dementia

9:44 The importance of an accurate diagnosis

13:30 Preparing for a doctor visit

15:30 Resources, support and caring for the caregiver

Featuring:

Anthony Caggiano, M.D., Ph.D., Chief Medical Officer and Head of R&D, Cognition Therapeutics

Christopher H. van Dyck, M.D., Yale University School of Medicine, Professor of Psychiatry, Neurology, and Neuroscience

Director of the Division of Aging and Geriatric Psychiatry; Director of the Alzheimer’s Disease Research Center

Anton P. Porsteinsson, M.D., University of Rochester School of Medicine and Dentistry, William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine

Director of the Alzheimer’s Disease Care, Research and Education Program (AD-CARE)

Index:

0:00 Introduction

1:47 Reactions to lecanemab results

3:48 Impact of targeting plaque

6:46 Potentially complementary strategies

11:24 Future of Alzheimer’s therapies

13:40 Conclusion

Featuring:

Anthony Caggiano, M.D., Ph.D., Chief Medical Officer and Head of R&D, Cognition Therapeutics

James Galvin, M.D., MPH, University of Miami Miller School of Medicine, Director of the Comprehensive Center for Brain Health

Principal Investigator of the SHIMMER Study

Index:

0:00 Introduction

1:09 What is DLB

3:13 Diagnostic Challenges

6:38 Potential Treatment Strategy

7:48 Designing a Clinical Trial

8:42 Conclusion